Physician profile
Jeffrey Mathews
NPI 1518968015
$5,161.05
in general payments reported to CMS, 2019-2025
25 companies · $34.37 in 2025
The $34.37 reported for 2025 was less than what a typical Rheumatology provider received nationally (typical 2025 total: $894).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2019: $1,680 · 2020: $946 · 2021: $814 · 2022: $1,488 · 2023: $182 · 2024: $15.72 · 2025: $34.37.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $232.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $232.24 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Abbvie INC. | $854.57 | 2019-2022 | |
| Janssen Biotech, INC. | $692.88 | 2019-2023 | Tremfya |
| Amgen INC. | $577.26 | 2019-2023 | Enbrel, Tavneos, Otezla |
| Genentech USA, INC. | $487.40 | 2019-2022 | |
| Novartis Pharmaceuticals Corporation | $466.03 | 2019-2023 | |
| Ucb, INC. | $461.64 | 2019-2023 | Cimzia |
| Lilly USA, LLC | $284.01 | 2019-2022 | |
| Glaxosmithkline, LLC. | $227.35 | 2019-2023 | Benlysta |
| Pfizer INC. | $172.65 | 2019-2022 | |
| Mallinckrodt Hospital Products INC. | $166.49 | 2022-2023 | Acthar |
| Astrazeneca Pharmaceuticals LP | $149.16 | 2021-2024 | Saphnelo |
| Radius Health, INC. | $119.26 | 2020-2025 | Tymlos |
| Horizon Therapeutics Plc | $112.55 | 2019-2022 | |
| Nevro Corp. | $72.66 | 2019 | |
| Organon LLC | $68.18 | 2021-2022 |
Show all 25 companies
| Company | General payments | Years | Top products |
|---|---|---|---|
| Celgene Corporation | $59.97 | 2019 | |
| Regeneron Healthcare Solutions, INC. | $45.50 | 2019 | |
| Genzyme Corporation | $39.91 | 2020-2021 | |
| Actelion Pharmaceuticals US, INC. | $25.16 | 2021 | |
| Gilead Sciences, INC. | $14.76 | 2019 | |
| Ultragenyx Pharmaceutical INC. | $13.50 | 2021 | |
| Merck Sharp & Dohme LLC | $12.93 | 2019 | |
| Tactile Systems Technology INC | $12.77 | 2021 | |
| E.R. Squibb & Sons, L.L.C. | $12.68 | 2020 | |
| Sobi, INC | $11.78 | 2019 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Jeffrey Mathews listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.